

(51) International Patent Classification:
C12N 15/113 (2010.01)(21) International Application Number:
PCT/US2021/065628(22) International Filing Date:
30 December 2021 (30.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/133,013 31 December 2020 (31.12.2020) US
63/179,100 23 April 2021 (23.04.2021) US
63/245,262 17 September 2021 (17.09.2021) US(71) Applicant: **DYNE THERAPEUTICS, INC.** [US/US];
1560 Trapelo Road, Waltham, MA 02451 (US).(72) Inventors: **SUBRAMANIAN, Romesh, R.**; 830 Winter Street, Waltham, MA 02451 (US). **WEEDEN, Timothy**; 830 Winter Street, Waltham, MA 02451 (US). **DESJARDINS, Cody, A.**; 830 Winter Street, Waltham, MA 02451 (US). **ZANOTTI, Stefano**; 830 Winter Street, Waltham, MA 02451 (US). **TANG, Kim**; 830 Winter Street, Waltham, MA 02451 (US). **QATANANI, Mohammed, T.**; 830 Winter Street, Waltham, MA 02451 (US). **QUINN, Brendan**; 830 Winter Street, Waltham, MA 02451 (US). **NAJIM, John**; 830 Winter Street, Waltham, MA 02451 (US).(74) Agent: **GE, Zhiyun** et al.; Wolf, Greenfield & Sacks, P.c.,
600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY




FIG. 25H

(57) Abstract: The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.